UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 0128, ~~2021~~2022

KALEIDO BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-38822	47-3048279
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

65 Hayden Avenue
Lexington, Massachusetts		02421
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 674-9000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 Par Value	KLDO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

OnThe ~~November 1, 2021, Kaleido Biosciences, Inc. (the “~~Company”) ~~announced~~has ~~its~~decided ~~financial~~to ~~results~~halt ~~for~~work ~~the~~on ~~third~~a ~~quarter~~planned ~~ended~~Phase ~~September~~2 ~~30,~~chronic ~~2021.~~obstructive ~~The~~pulmonary ~~full~~disease ~~text~~(COPD) ofstudy ~~the~~and ~~press~~terminate ~~release~~its ~~issued~~agreement ~~in connection~~ with the ~~announcement~~COPD isFoundation. These ~~furnished~~decisions aswere ~~Exhibit~~made ~~99.1~~in order to ~~this~~re-align ~~Current~~resources ~~Report~~and onfocus ~~Form~~the ~~8-K~~Company's efforts.

The information in Item 2.02 of this Form 8-K (including Exhibits 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished herewith
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			KALEIDO BIOSCIENCES, INC.
			Kaleido Biosciences, Inc.
Date:	~~November~~January 128, ~~2021~~2022	By:	/s/ ~~William~~Daniel ~~Duke, Jr~~L. Menichella
			William Duke, Jr.Chief Financial Officer(Principal Financial and Accounting Officer)
			Chief Executive Officer, President and Director

Filing Compare · Kaleido Biosciences, Inc.